Drugs / PHN-012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07127874 | Sep 2025 → Sep 2027 expected | colon carcinoma, malignant pancreatic neoplasm, non-small cell lung carcinoma | Pheon Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PHN-012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07127874 ↗ |
| Route | Intravenous | “PHN-012 is administered intravenously” NCT07127874 ↗ |